THE EFFECT OF CARVEDILOL ON MORBIDITY AND MORTALITY IN PATIENTS WITH CHRONIC HEART FAILURE
暂无分享,去创建一个
ICHAEL | Ichael | ohn | Eil | Dward | G. M. | Ay | B R. | RISTOW | AY | C N. | OHN | ILSON | C S. | OLUCCI | F B. | OWLER | DWARD | G M. | ILBERT | EIL | S H. | HUSTERMAN | Ilbert | ilson | C. S. | S. H. | C. N | Ristow | B. R. | Olucci | Owler | F. B | S. H. | Husterman | C. N | B. R | G. M. | Ristow | C. S.
[1] M. Packer. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. , 1992, Journal of the American College of Cardiology.
[2] Hung‐Yuan Cheng,et al. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. , 1992, The Journal of pharmacology and experimental therapeutics.
[3] Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1987, The New England journal of medicine.
[4] M. Metra,et al. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. , 1994, Journal of the American College of Cardiology.
[5] H. Krum,et al. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. , 1995, Circulation.
[6] P. O'Brien,et al. A multiple testing procedure for clinical trials. , 1979, Biometrics.
[7] T. Levine,et al. Effects of long-term monotherapy with enalapril, metoprolol, and digoxin on the progression of left ventricular dysfunction and dilation in dogs with reduced ejection fraction. , 1994, Circulation.
[8] Salim Yusuf,et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.
[9] G. Feuerstein,et al. Cardioprotective effects of carvedilol, a novel beta adrenoceptor antagonist with vasodilating properties, in anaesthetised minipigs: comparison with propranolol. , 1992, Cardiovascular research.
[10] K. Swedberg,et al. PROLONGATION OF SURVIVAL IN CONGESTIVE CARDIOMYOPATHY BY BETA-RECEPTOR BLOCKADE , 1979, The Lancet.
[11] M. Bristow. Pathophysiologic and pharmacologic rationales for clinical management of chronic heart failure with beta-blocking agents. , 1993, The American journal of cardiology.
[12] J. A. Thomas,et al. Plasma norepinephrine in congestive heart failure. , 1978, The American journal of cardiology.
[13] R. Bain,et al. Effects of vesnarinone on morbidity and mortality in patients with heart failure , 1993 .
[14] D.,et al. Regression Models and Life-Tables , 2022 .
[15] D. DeMets,et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. , 1991, The New England journal of medicine.
[16] E. Braunwald,et al. The effect of beta adrenergic blockade on patterns of urinary sodium excretion. Studies in normal subjects and in patients with heart disease. , 1966, Annals of internal medicine.
[17] P. Armitage,et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. , 1976, British Journal of Cancer.
[18] G. Plotnick,et al. Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial. , 1994, Journal of the American College of Cardiology.
[19] K Caidahl,et al. Long-term beta-blockade in dilated cardiomyopathy. Effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol. , 1989, Circulation.
[20] P. Grayburn,et al. Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. , 1994, Journal of the American College of Cardiology.
[21] E. Varnauskas,et al. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. , 1975, British heart journal.
[22] N. Dhalla,et al. Ventricular dysfunction and necrosis produced by adrenochrome metabolite of epinephrine: relation to pathogenesis of catecholamine cardiomyopathy. , 1981, American heart journal.
[23] F. Tristani,et al. Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure. Results of a Veterans Administration Cooperative Study , 1987 .
[24] K. Swedberg,et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy , 1993, The Lancet.
[25] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[26] B. Parsons,et al. Adrenergic Effects on the Biology of the Adult Mammalian Cardiocyte , 1992, Circulation.
[27] M. Borgers,et al. Nebivolol Increases Survival in Cardiomyopathic Hamsters with Congestive Heart Failure , 1991, Journal of cardiovascular pharmacology.
[28] W. French,et al. Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Bucindolol Investigators. , 1994, Circulation.
[29] J. Cohn,et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. , 1984, The New England journal of medicine.
[30] M. Pike,et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.
[31] R. Willette,et al. The pharmacology of carvedilol , 2005, European Journal of Clinical Pharmacology.
[32] D. Renlund,et al. beta-adrenergic receptor regulation and left ventricular function in idiopathic dilated cardiomyopathy. , 1993, The American journal of cardiology.
[33] D. Renlund,et al. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. , 1995, Journal of the American College of Cardiology.
[34] D. Renlund,et al. Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. , 1991, Circulation.